Skye Bioscience and Redx Pharma agreed to combine, creating a new public company, Fibrx Therapeutics, with about $125 million in financing to advance fibrotic disease assets. The deal follows Redx’s development momentum and shifts the combined platform toward later-stage program execution, with investors focused on milestones that could support regulatory paths and commercial expansion.